EDAP to Participate in the UBS Global Healthcare Conference
Rhea-AI Summary
EDAP (Nasdaq: EDAP) will participate in the UBS Global Healthcare Conference held November 10-13, 2025 in Palm Beach Gardens, Florida. CEO Ryan Rhodes and CFO Ken Mobeck are scheduled to host one-on-one investor meetings on Monday, November 10, 2025 at PGA National Resort Hotel.
Meetings are 1x1 investor sessions; registration is via UBS for clients or through a UBS sales representative.
Positive
- None.
Negative
- None.
News Market Reaction 13 Alerts
On the day this news was published, EDAP declined 1.77%, reflecting a mild negative market reaction. Argus tracked a trough of -16.9% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $79M at that time. Trading volume was elevated at 2.3x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
EDAP to Participate in the UBS Global Healthcare Conference
Company to Host 1x1 Investor Meetings on Monday, November 10th, 2025
AUSTIN, Texas, October 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, and Ken Mobeck, Chief Financial Officer, are scheduled to host 1x1 investor meetings at the upcoming UBS Global Healthcare Conference, which is being held November 10-13, 2025, in Palm Beach Gardens, Florida.
Date: Monday, November 10th
Format: 1x1 investor meetings
Location: PGA National Resort Hotel, Palm Beach Gardens, Florida
Registration: Click here to register for the conference (for UBS clients only), or please contact your UBS sales representative.
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
FAQ
When will EDAP (Nasdaq: EDAP) hold investor meetings at the UBS Global Healthcare Conference in 2025?
Who from EDAP will attend the UBS Global Healthcare Conference on November 10, 2025?
Where are EDAP's investor meetings at the UBS Global Healthcare Conference taking place?
How can investors register for EDAP meetings at the UBS Global Healthcare Conference November 2025?
What format will EDAP use for investor interactions at the UBS Global Healthcare Conference?
What are the dates of the UBS Global Healthcare Conference where EDAP is participating?
